Navigation Links
Orexigen Therapeutics to Present at the UBS Global Healthcare Conference
Date:5/17/2013

SAN DIEGO, May 17, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the UBS Global Healthcare Conference in New York. The presentation is scheduled for Wednesday, May 22nd at 11 a.m. Eastern Time. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's Web site at www.orexigen.com. A replay will be available for 14 days after the event.

About Orexigen® Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave®, which has completed Phase 3 clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment (SPA) for the Light Study, the Contrave cardiovascular outcomes trial. The Company's other product candidate, Empatic™, has completed Phase 2 clinical trials. Further information about the Company can be found at www.orexigen.com.Orexigen Contact:

Media Contact:  McDavid Stilwell

Denise PowellVP, Corporate Communications and Business Development

BrewLife(858) 875-8629

(510) 703-9491


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
2. Orexigen Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
3. Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
4. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
5. Orexigen Therapeutics Schedules August 7, 2012 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2012
6. Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012
7. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
8. Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
9. Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012
10. Orexigen Therapeutics To Host Analyst Day Event on December 18, 2012
11. Orexigen Therapeutics to Present at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2020)... ... 2020 , ... Cataract is the world's leading cause of blindness , ... the United States, more than 25 million Americans are estimated to have cataract, according ... Problems .” As the population in America continues to age, the number of cataract ...
(Date:5/21/2020)... ... May 21, 2020 , ... ... needs in the field of urology, today announced that Naveen Divakaruni, D.O., Advocate ... Excellence. The designation recognizes that Dr. Divakaruni has achieved a high level of ...
(Date:5/16/2020)... ... May 17, 2020 , ... Athletic ... can provide primary care, injury and illness prevention, wellness promotion and education, ... and medical conditions. Secondary schools and colleges/universities employ a large majority of ...
Breaking Medicine Technology:
(Date:5/21/2020)... Pa. (PRWEB) , ... May 21, 2020 , ... ... Inc. and an industry leader in cancer biomarker assays, announced today that Cigna ... list. Cigna Corporation is a global health service company dedicated to improving the ...
(Date:5/21/2020)... (PRWEB) , ... May 21, 2020 , ... ESO ... and hospitals, today announced the findings of its 2020 ESO Fire Service Index ... of EMS calls versus fire-related calls, first apparatus turnout time and travel time, the ...
(Date:5/17/2020)... ... May 18, 2020 , ... R3 Stem Cell International is ... clinic. There are two program options for patients and their families, which are ... is unclear exactly what causes Autism Spectrum Disorder (ASD), there are several recent ...
(Date:5/15/2020)... ... ... COVID-19 has made people feel fearful, but Rieke Office Interiors (ROI) is ... back to work safely. Their unique line of SafeSpace™ PPE equipment for the office ... settings. , Everyone needs to be able to get back to work and to ...
(Date:5/15/2020)... TAMPA, Fla. (PRWEB) , ... May 15, 2020 ... ... in Tampa Bay, placed the final beam atop the hospital’s new six-story, 300,000 ... Fletcher Ave. and Bruce B. Downs Boulevard. The topping off celebrates the structural ...
Breaking Medicine News(10 mins):